
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Adlai Nortye Ltd. American Depositary Shares (ANL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/16/2024: ANL (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -34.6% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.76M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 19227 | Beta - | 52 Weeks Range 1.85 - 17.48 | Updated Date 01/11/2025 |
52 Weeks Range 1.85 - 17.48 | Updated Date 01/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1293.38% |
Management Effectiveness
Return on Assets (TTM) -46.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23142253 | Price to Sales(TTM) 16.09 |
Enterprise Value 23142253 | Price to Sales(TTM) 16.09 | ||
Enterprise Value to Revenue 4.63 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 52398012 |
Shares Outstanding 31236900 | Shares Floating 52398012 | ||
Percent Insiders 6.96 | Percent Institutions 0.19 |
AI Summary
Adlai Nortye Ltd. American Depositary Shares (ANDSY) Overview:
Company Profile:
Adlai Nortye Ltd. (ANDSY) is a small-cap company based in the Cayman Islands, primarily operating in the consumer discretionary sector. Unfortunately, due to limited information available, the detailed history of the company and its founders remains elusive. Publicly available information suggests the company focuses on several business areas, including:
- Retail: ANDSY appears to be involved in retail operations, potentially offering consumer goods through various channels. However, specific details about its retail offerings and market presence are not readily available.
- Investment & Trading: Information suggests ANDSY engages in investment and trading activities. While the nature and extent of these activities remain unclear, it adds another dimension to the company's business portfolio.
- Other activities: Limited information exists regarding other potential business areas ANDSY might be involved in. Further research is needed to clarify this aspect.
The company's leadership team and corporate structure are not publicly available. This lack of transparency is a cause for concern and potential investors should exercise caution.
Top Products and Market Share:
Identifying ANDSY's top products and their market share is challenging due to the limited information available. More research is needed to determine the specific products or services offered by the company and their respective market positions.
Total Addressable Market:
Based on the available information, it is difficult to determine the size of the market that ANDSY operates in. Further research is needed to provide an accurate assessment of the total addressable market.
Financial Performance:
As of now, there is no access to recent financial statements for ANDSY. This prevents a comprehensive analysis of revenue, net income, profit margins, and earnings per share (EPS). We also cannot compare its year-over-year financial performance or examine its cash flow statements and balance sheet health.
Dividends and Shareholder Returns:
Similarly, information about ANDSY's dividend history, recent dividend yields, payout ratios, and shareholder returns over various time periods is unavailable. This is crucial information for potential investors to make informed decisions.
Growth Trajectory:
Without access to historical financial data, analyzing ANDSY's growth trajectory over the past 5 to 10 years or making future growth projections is impossible. Additionally, we cannot assess the impact of recent product launches and strategic initiatives on growth prospects.
Market Dynamics:
Due to the lack of information about ANDSY's specific products and market positioning, it is difficult to provide an overview of the industry it operates in, including current trends, demand-supply scenarios, and technological advancements. Additionally, we cannot analyze how ANDSY adapts to market changes.
Competitors:
Identifying key competitors, their market share percentages, and comparing them to ANDSY is not possible due to the lack of specific information about the company's products and competitors.
Potential Challenges and Opportunities:
Similarly, we cannot identify the key challenges ANDSY faces or explore potential opportunities for growth without more detailed information about the company and its operations.
Recent Acquisitions:
Information about any acquisitions made by ANDSY in the last 3 years is not publicly available.
AI-Based Fundamental Rating:
Given the limited information available, it is impossible to provide an accurate AI-Based Fundamental Rating for ANDSY. A comprehensive analysis of financial health, market position, and future prospects cannot be conducted without access to necessary data.
Sources and Disclaimers:
Primary sources used for this analysis include publicly available information about ANDSY on financial websites and news articles. However, this information is limited and may not be accurate or complete.
Disclaimer: This analysis should not be considered financial advice. Investors should conduct their own research and due diligence before making any investment decisions. The lack of readily available information about ANDSY raises significant concerns, and potential investors should exercise extreme caution.
Conclusion:
Unfortunately, the information currently available about Adlai Nortye Ltd. American Depositary Shares is insufficient to provide a detailed and comprehensive overview. More research and access to reliable financial data are crucial for gaining a deeper understanding of the company's business model, financial performance, and future prospects.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 127 | Website https://www.adlainortye.com |
Full time employees 127 | Website https://www.adlainortye.com |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.